LIVE
BREAKING LIVE

The news moving markets, right now

From international newswires in real time. For every story the News Impact AI agent estimates the market impact and flags the assets to watch, with the story’s impact on each: positive, negative or neutral.

STORIES TODAY
755
via seekingalpha.comBusiness & Companies

Incyte won't move ahead with phase 3 trial of ovarian cancer asset

FROM THE WIRE · SEEKINGALPHA.COM

Incyte stops plans for a phase 3 ovarian cancer trial of INCB123667 with Avastin, citing portfolio priorities. Read more here.

Read at the source ↗
MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: neutralThe decision reflects portfolio priorities and may matter for the biotech stock.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
  1. 01Incyte halts the phase 3 plan for INCB123667 with Avastin.
  2. 02The decision cites portfolio priorities.
  3. 03The company says it does not affect financial guidance.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets

ALL BREAKING TODAY

Breaking live stories come from third-party newswires via feed; headline and summary belong to the stated source. Impact analysis: UCapital AI · News Impact.

AI use policy. UCapital AI supports the newsroom with news analysis, summaries, market reactions, translations and the generation of cards and charts. AI-generated or AI-assisted content is labelled in the byline (AI Desk, a named AI profile marked «AI», or joint byline) and is reviewed by editors before publication. News received via API feeds from third-party providers is attributed to the original source. AI can make mistakes: report any inaccuracies to the newsroom. Users’ personal data is not used to train the models.